Longitudinal Multi-Omics Profiling of Aqueous Humor Implicates GALNS Depletion as a Pro-Fibrotic Mediator of

Yujuan Huang1,2, Mi Gui1, Xiangbin Kong2

  • 1Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China.

Abstract

Insights

Anti-vascular endothelial growth factor (VEGF) therapy for proliferative diabetic retinopathy (PDR) may worsen fibrosis. This study identified GALNS depletion as a potential pro-fibrotic marker after anti-VEGF treatment in PDR patients.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Biochemistry

Background:

  • Preoperative anti-vascular endothelial growth factor (VEGF) therapy in proliferative diabetic retinopathy (PDR) can lead to fibrovascular contraction, complicating treatment.
  • Understanding the molecular changes induced by anti-VEGF therapy is crucial for managing PDR complications.

Purpose of the Study:

  • To characterize proteo-metabolomic alterations following anti-VEGF therapy in PDR.
  • To validate potential molecular candidates associated with PDR progression or improvement.
  • To investigate the functional role of key molecules in fibrosis.

Main Methods:

  • Aqueous humor samples from PDR patients were analyzed using data-independent acquisition (DIA) proteomics and widely targeted metabolomics before and after anti-VEGF (aflibercept) treatment.
  • Molecules showing significant changes were classified as 'aggravation-type' or 'improvement-type'.
  • Validation was performed using parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) in an independent cohort, with functional assessment of GALNS via siRNA knockdown.

Main Results:

  • Thirty-eight molecules, including 5 proteins and 33 metabolites, were identified. Three molecules (CAST, GALNS, 3-hydroxypropanoic acid [3-HPA]) were classified as 'aggravation-type'.
  • Only GALNS was robustly validated across cross-sectional and longitudinal analyses, showing depletion post-treatment in PDR patients with tractional retinal detachment.
  • GALNS knockdown in fibroblasts increased pro-fibrotic markers (α-SMA, collagen I), enhanced cell migration, and promoted contractility.

Conclusions:

  • GALNS depletion is identified as a potential pro-fibrotic molecule associated with anti-VEGF therapy in PDR.
  • GALNS may serve as a candidate biomarker for perioperative risk stratification in PDR patients undergoing anti-VEGF treatment.
  • CAST and 3-HPA require further investigation in larger cohorts.

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...